Clearside Biomedical, Inc. - Common Stock (CLSD)
Frequently Asked Questions About Clearside Biomedical, Inc. - Common Stock (CLSD)
Does Clearside Biomedical have partnerships?
Yes, Clearside Biomedical has established partnerships with various organizations to enhance its development capabilities and market access. Collaborations may include research partnerships, co-development agreements, and alliances with larger pharmaceutical companies to expand its reach in the ophthalmic market.
How does Clearside Biomedical engage with its investors?
Clearside Biomedical actively engages with its investors through regular updates, earnings calls, and presentations at investor conferences. The company is committed to transparency and communication, providing stakeholders with insights into its business performance, clinical developments, and strategic objectives.
How does Clearside Biomedical ensure regulatory compliance?
Clearside Biomedical ensures regulatory compliance by adhering to the rigorous standards set by the FDA and other regulatory bodies throughout its drug development process. The company employs dedicated professionals with expertise in regulatory affairs to manage submissions and ensure alignment with legal and ethical requirements.
How does Clearside Biomedical fund its operations?
Clearside Biomedical funds its operations through a combination of equity financing, partnerships, and collaborations. By leveraging public market funding and strategic alliances, the company has been able to support its research and development initiatives effectively.
How is Clearside Biomedical positioned in the ophthalmic sector?
Clearside Biomedical is positioned as an innovative player in the ophthalmic sector, specializing in unique delivery systems that improve drug efficacy and patient outcomes. Its focus on retinal diseases differentiates it from competitors, and its proprietary technology offers a distinct advantage in the growing ophthalmic market.
Is Clearside Biomedical publicly traded?
Yes, Clearside Biomedical is publicly traded on the Nasdaq under the ticker symbol CLSD. The company began trading on the Nasdaq in June 2017, providing it with access to public capital markets to support its growth and development projects.
What are Clearside Biomedical’s future plans?
Clearside Biomedical is focused on advancing its clinical pipeline, expanding its product offerings, and enhancing its manufacturing capabilities. The company aims to leverage its unique drug delivery technology to introduce new therapies while pursuing partnerships and collaborations to accelerate growth.
What are the key technologies used by Clearside Biomedical?
Clearside Biomedical leverages its proprietary suprachoroidal drug delivery technology, which allows for the targeted delivery of therapeutic agents to the retina. This technology aims to enhance therapeutic efficacy and minimize side effects compared to traditional methods of drug administration.
What are the main diseases targeted by Clearside Biomedical?
Clearside Biomedical primarily targets retinal diseases, including macular edema associated with uveitis, diabetic retinopathy, and age-related macular degeneration. These conditions represent significant therapeutic areas with considerable unmet medical needs, driving the company’s research focus.
What does Clearside Biomedical, Inc. do?
Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for serious diseases of the eye, particularly in the area of retinal disease. The company employs its proprietary Clearside microparticle technology to enhance drug delivery to the retina, which can improve treatment outcomes while minimizing systemic exposure.
What is Clearside Biomedical’s lead product?
Clearside Biomedical’s lead product is Xipere (triamcinolone acetonide suprachoroidal injectable suspension), which is indicated for the treatment of macular edema associated with uveitis. Approved by the FDA in 2021, Xipere utilizes the company’s proprietary microsphere technology to deliver medication directly to the back of the eye, targeting the site of disease.
What is the company’s pipeline of research projects?
Clearside Biomedical has developed a robust pipeline of research projects aimed at treating various ocular conditions through its unique drug delivery platform. In addition to Xipere, the pipeline includes several investigational therapies undergoing clinical development targeting diseases like retinal vein occlusion and diabetic macular edema.
What is the market potential for Clearside Biomedical’s products?
The market potential for Clearside Biomedical's products is significant, given the growing prevalence of retinal diseases and the increasing demand for effective treatments. As the population ages and diabetes rates rise, the need for innovative therapies creates a favorable landscape for the company’s offerings.
What is the status of Clearside's clinical trials?
Clearside Biomedical has been actively conducting clinical trials for its drug candidates, including Xipere and its pipeline programs. These trials are essential for assessing the safety and efficacy of their treatments, and the company regularly updates investors and the public on trial progress and results.
When was Clearside Biomedical founded?
Clearside Biomedical was founded in 2011. Since its inception, the company has focused on innovating drug delivery technologies and advancing treatments for retinal diseases, carving a niche in the biopharma industry with its specialized methods.
Where is Clearside Biomedical located?
Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia. This location supports the company’s research and development efforts, as well as its corporate operations, allowing it to efficiently collaborate with healthcare professionals and regulatory bodies involved in the eye care industry.
Who are Clearside Biomedical’s competitors?
Clearside Biomedical faces competition from several biotech and pharmaceutical companies that are also involved in the development of retinal therapies. Key competitors may include companies specializing in ophthalmic drugs, such as Regeneron Pharmaceuticals, Novartis, and Genentech, as they also target similar disease areas.
Who are the key executives at Clearside Biomedical?
Clearside Biomedical’s leadership team is comprised of experienced professionals from the biopharmaceutical industry. This team, led by CEO and other senior executives, bring a wealth of knowledge in drug development, business strategy, and regulatory affairs, collectively guiding the company toward its strategic goals.
What is the current price of Clearside Biomedical, Inc. - Common Stock?
The current price of Clearside Biomedical, Inc. - Common Stock is 0.8810
When was Clearside Biomedical, Inc. - Common Stock last traded?
The last trade of Clearside Biomedical, Inc. - Common Stock was at 2:51 pm EDT on April 4th, 2025
What is the market capitalization of Clearside Biomedical, Inc. - Common Stock?
The market capitalization of Clearside Biomedical, Inc. - Common Stock is 54.33M
How many shares of Clearside Biomedical, Inc. - Common Stock are outstanding?
Clearside Biomedical, Inc. - Common Stock has 61.67M shares outstanding.